YiChang HEC ChangJiang Pharmaceutical’s Yiqibuvir Receives NMPA Review for Hepatitis C Treatment
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that the National Medical...
Company
Everest Medicines’ Partner Venatorx Pharmaceuticals Receives FDA Priority Review for Cefepime-Taniborbactam
China-based Everest Medicines (HKG: 1952) announced that its partner, Venatorx Pharmaceuticals, has received acceptance from...
CStone Pharmaceuticals Reports 2023 Interim Financials and Business Milestones
China-based CStone Pharmaceuticals (HKG: 2616) has announced its 2023 interim financial results alongside key business...
HitGen Inc. Partners with Nested Therapeutics for Precision Medicine Research
China-based HitGen Inc. (SHA: 688222) has announced a research service agreement with Cambridge, Massachusetts-based precision...
Simcere Pharmaceutical’s Cosela Receives NMPA Review for ES-SCLC Indication
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced that the National Medical Products Administration (NMPA)...
Suzhou Leadsynbio Secures Series D Funding to Boost R&D and Market Presence
Suzhou Leadsynbio Technology Co., Ltd, a specialist in synthetic biology, has reported raised hundreds of...
SinoMab BioScience Receives NMPA Approval for Phase I Clinical Study of SM17 Asthma Therapy
Hong Kong-based biotech company SinoMab BioScience Ltd (HKG: 3681) has announced that it has received...
Jiangsu Hengrui Pharmaceuticals Strikes Licensing Deal with One Bio Inc. for TSLP-Targeted mAb SHR1905
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced a significant licensing agreement with...
J&J Subsidiary Janssen Wins FDA Approval for Akeega in BRCA-Positive mCRPC Treatment
The US Food & Drug Administration (FDA) has granted marketing approval to Johnson & Johnson...
Medivir’s Fostrox in Combination with Lenvima Shows Promise in Phase IIa HCC Trial
Sweden-based Medivir (STO: MVIR) has released interim data from a Phase IIa trial evaluating the...
AstraZeneca to Invest Additional USD 250 Million in Qingdao for Aerosol Production Plant
UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) is set to invest an additional USD 250...
Eli Lilly Expands Portfolio with Acquisitions of Sigilon Therapeutics and Versanis Bio
Eli Lilly (NYSE: LLY) has completed the separate purchases of US compatriots Sigilon Therapeutics (NASDAQ:...
Pfizer’s Elrexfio Earns Accelerated FDA Approval for Relapsed/Refractory Multiple Myeloma
This week, Pfizer (NYSE: PFE) received an accelerated approval from the US Food and Drug...
Novartis Acquires Chinook Therapeutics for $3.2 Billion, Eyes Kidney Disease Market
Switzerland-based pharmaceutical major Novartis (NYSE: NVS) has successfully completed the scheduled purchase of US-based kidney...
Janssen’s Talvey Receives FDA Accelerated Approval for Relapsed/Refractory Multiple Myeloma
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) announced last week that it...
Novo Nordisk to Acquire Inversago Pharma in a Deal Valued Up to USD 1.1 Billion
Denmark’s leading pharmaceutical company, Novo Nordisk (NYSE: NVO), has reached an agreement to acquire Canada-based...
Telix Pharmaceuticals and Grand Pharma Initiate Phase III Trial for Illucix in China
Australian biotechnology company Telix Pharmaceuticals Ltd (ASX: TLX) and its China market partner, Grand Pharmaceutical...
Mirxes Holding Company Receives FDA Breakthrough Device Designation for GASTROClea
Singapore-based RNA technology company, Mirxes Holding Company Ltd, which specializes in blood-based miRNA test kit...
Bio-Thera Solutions’ BAT8006 Shows Positive Phase I Results in Solid Tumor Treatment
China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced positive Phase I clinical data for BAT8006...
Vcanbio Receives Orphan Drug Designation for VUM02 in Idiopathic Pulmonary Fibrosis Treatment
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that it has...